Market Overview:
The global human hepatitis B immunoglobulin market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of hepatitis B infections, rising awareness about preventive measures for hepatitis B, and technological advancements in the field of diagnostics and treatment. Based on type, the global human hepatitis B immunoglobulin market is segmented into 100IU/bottle human hepatitis B immunoglobulin (HBIG), 200IU/bottle human hepatitis B immunoglobulin (HBIG), and 400IU/bottle human hepatitis B immunoglobulin (HBIG). The 100IU/bottle HBIG segment is expected to account for the largest share of the global market in 2018. This can be attributed to its low cost as compared to other types of HBIGs available in the market.
Product Definition:
Human hepatitis B immunoglobulin (HBIG) is a preparation of concentrated antibodies to the hepatitis B virus. It is used to prevent or reduce the severity of an infection with the virus in people who have been exposed to it.
100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG):
Human Hepatitis B Immunoglobulin (HBIG) is a type of immunoglobulin used to treat chronic hepatitis B. Chronic hepatitis means that the disease has not been cured and the patient is still infected with HBV DNA, which may lead to liver cancer or other serious complications.
200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG):
200IU/bottle Human Hepatitis B Immunoglobulin (HBIG) is used in the treatment of chronic (lasting more than 6 months) hepatitis B. Chronic hepatitis means that your body is unable to fight off infection and can damage liver cells.
According to the Centers for Disease Control.
Application Insights:
The application segment includes hepatitis B carrier, hepatitis B close contacts and others. The former two segments together accounted for the largest share in the global market in 2017 owing to increasing prevalence of chronic HBV infection. According to WHO, an estimated 170 million people are suffering from chronic HBV infection across the globe. In addition, according to U.S Department of Health & Human Services (HHS), around 3% of population is a carrier of HBV which can infect other individuals through unprotected sexual contact or sharing contaminated needles without being diagnosed or treated by a doctor.
On other hand, hepatitis B close contacts segment is expected register fastest CAGR during forecast period owing to high availability and adoption of antiviral drugs among individuals at risk for developing chronic HBV infection such as patients with HIV/AIDS.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of manufacturers and suppliers coupled with high awareness levels regarding HBV immunoglobulin therapies are some factors attributing to its continued dominance over the forecast period.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to increasing investments by leading players, rising demand for HBIG products among people living with chronic diseases such as hepatitis, and an increase in healthcare expenditure. Moreover, growing awareness about hepatitis B vaccination programs will also propel regional growth over the next eight years. ‘‘‘‘‘ €œœœ‘‘—'—' XXXXXXXThe author would like to thank you for reading this article till end.
Growth Factors:
- Increasing incidence of hepatitis B infections across the globe
- Growing awareness about the benefits of human hepatitis B immunoglobulin therapy
- Rising demand for prophylactic and therapeutic human hepatitis B immunoglobulin products
- Technological advancements in manufacturing and packaging of human hepatitis B immunoglobulin products
- increasing number of mergers and acquisitions among key players in the market
Scope Of The Report
Report Attributes
Report Details
Report Title
Human Hepatitis B Immunoglobulin Market Research Report
By Type
100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG), 200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG), 400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
By Application
Hepatitis B Carrier, Hepatitis B Close Contacts
By Companies
Baxter, CSL, Bayer, Grifols, Octapharma, Shanghai RAAS, Hualan Biological, China Biologic, Tiantan Biologic, Shuanglin Bio-pharmacy, Baxter, Boya Bio-pharmaceutical, Shanghai Institute of Biological
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
138
Number of Tables & Figures
97
Customization Available
Yes, the report can be customized as per your need.
Global Human Hepatitis B Immunoglobulin Market Report Segments:
The global Human Hepatitis B Immunoglobulin market is segmented on the basis of:
Types
100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG), 200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG), 400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hepatitis B Carrier, Hepatitis B Close Contacts
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Baxter
- CSL
- Bayer
- Grifols
- Octapharma
- Shanghai RAAS
- Hualan Biological
- China Biologic
- Tiantan Biologic
- Shuanglin Bio-pharmacy
- Baxter
- Boya Bio-pharmaceutical
- Shanghai Institute of Biological
Highlights of The Human Hepatitis B Immunoglobulin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
- 200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
- 400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
- By Application:
- Hepatitis B Carrier
- Hepatitis B Close Contacts
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Human Hepatitis B Immunoglobulin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Human hepatitis B immunoglobulin is a type of antibody that helps the body fight against hepatitis B.
Some of the major players in the human hepatitis b immunoglobulin market are Baxter, CSL, Bayer, Grifols, Octapharma, Shanghai RAAS, Hualan Biological, China Biologic, Tiantan Biologic, Shuanglin Bio-pharmacy, Baxter, Boya Bio-pharmaceutical, Shanghai Institute of Biological.
The human hepatitis b immunoglobulin market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Human Hepatitis B Immunoglobulin Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Human Hepatitis B Immunoglobulin Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Human Hepatitis B Immunoglobulin Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Human Hepatitis B Immunoglobulin Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Human Hepatitis B Immunoglobulin Market Size & Forecast, 2020-2028
4.5.1 Human Hepatitis B Immunoglobulin Market Size and Y-o-Y Growth
4.5.2 Human Hepatitis B Immunoglobulin Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
5.2.2 200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
5.2.3 400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hepatitis B Carrier
6.2.2 Hepatitis B Close Contacts
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Human Hepatitis B Immunoglobulin Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Human Hepatitis B Immunoglobulin Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
9.6.2 200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
9.6.3 400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hepatitis B Carrier
9.10.2 Hepatitis B Close Contacts
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
10.6.2 200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
10.6.3 400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hepatitis B Carrier
10.10.2 Hepatitis B Close Contacts
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
11.6.2 200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
11.6.3 400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hepatitis B Carrier
11.10.2 Hepatitis B Close Contacts
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
12.6.2 200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
12.6.3 400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hepatitis B Carrier
12.10.2 Hepatitis B Close Contacts
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
13.6.2 200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
13.6.3 400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hepatitis B Carrier
13.10.2 Hepatitis B Close Contacts
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Human Hepatitis B Immunoglobulin Market: Competitive Dashboard
14.2 Global Human Hepatitis B Immunoglobulin Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Baxter
14.3.2 CSL
14.3.3 Bayer
14.3.4 Grifols
14.3.5 Octapharma
14.3.6 Shanghai RAAS
14.3.7 Hualan Biological
14.3.8 China Biologic
14.3.9 Tiantan Biologic
14.3.10 Shuanglin Bio-pharmacy
14.3.11 Baxter
14.3.12 Boya Bio-pharmaceutical
14.3.13 Shanghai Institute of Biological
